Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Centrus Energy Corp (LEU) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Centrus Energy Corp — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $303 (market cap $39.89B), while Centrus Energy Corp trades at $170.74 (market cap $3.37B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 11.8× Centrus Energy Corp's market cap. Which is the better fit depends on your goals.
| ALNY | LEU | |
|---|---|---|
Market Cap | $39.89B | $3.37B |
Sector | Health | Energy |
52-Week High | $491.22 | $436.00 |
52-Week Low | $278.09 | $146.61 |
Enterprise Value | $38.15B | $2.68B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
Centrus Energy (LEU) trades at $171.05, down 1.45% on the day, with a neutral technical outlook. The company recently secured a major Department of Energy contract valued over $1 billion and is set to join the S&P SmallCap 600 index. While Q1 2026 earnings beat expectations, Q4 2025 was a significant miss. Valuation ratios appear elevated with a P/E of 62.2 and P/S of 8.05. Operating cash flow was positive in 2025 but turned negative in 2026 projections.
The outlook is mixed; strong government contracts and index inclusion provide tailwinds, but high valuation and inconsistent earnings pose risks. Analyst consensus is a Buy with a $224.50 price target, suggesting potential upside, though execution on new contracts and profitability trends will be critical for sustained growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Centrus Energy Corp
Centrus Energy is a leading supplier of nuclear fuel and services for the global power industry. It specializes in supplying low-enriched uranium and developing next-generation fuels for advanced nuclear reactors.
Read more on LEU →
